Cargando…

Clinical Analysis of Uncommon Epidermal Growth Factor Receptor Mutations in 16 Cases of Nonsmall Cell Lung Cancer

Detalles Bibliográficos
Autores principales:	Hu, Ai-Min, Li, Yun-Song, Zhao, Dan, Hu, Fan-Bin, Wang, Qun-Hui, Li, Bao-Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5912048/ https://www.ncbi.nlm.nih.gov/pubmed/29664067 http://dx.doi.org/10.4103/0366-6999.229887

Ejemplares similares

Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait
por: Al-Temaimi, Rabeah, et al.
Publicado: (2016)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Erratum: Epidermal growth factor receptor mutations in nonsmall cell lung carcinoma patients in Kuwait
Publicado: (2016)

Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer
por: Dang, Yutao, et al.
Publicado: (2020)

Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer
por: Kim, Seo Yun, et al.
Publicado: (2017)

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer
por: Ye, Liang, et al.
Publicado: (2017)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
por: Yu, Limeng, et al.
Publicado: (2023)

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases
por: Usui, Kazuhiro, et al.
Publicado: (2011)

Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
por: Kobayashi, Kunihiko, et al.
Publicado: (2013)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis: Erratum
Publicado: (2017)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer
por: Li, Xi, et al.
Publicado: (2023)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

High Epidermal Growth Factor Receptor Mutation Rates in Peruvian Patients With Non–Small-Cell Lung Cancer: Is It a Matter of Asian Ancestry?
por: Pinto, Joseph A., et al.
Publicado: (2017)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing
por: Righi, Luisella, et al.
Publicado: (2013)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation
por: Ko, How-Wen, et al.
Publicado: (2022)

Long‐term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation‐positive lung adenocarcinoma
por: Shijubou, Naoki, et al.
Publicado: (2021)

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer
por: Zhu, Chao, et al.
Publicado: (2019)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
por: Zhang, Yan, et al.
Publicado: (2017)

Cutaneous Metastasis as the First Symptom: An Uncommon Presentation of Squamous Cell Lung Cancer
por: Wang, Feng, et al.
Publicado: (2017)

Auricular Schwannoma: An Uncommon Location
por: Reyna-Rodriguez, Irving Llibran, et al.
Publicado: (2020)

Uncommon Location of Bowenoid Papulosis
por: Meira, Sonia de la Fuente, et al.
Publicado: (2022)

Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
por: Lei, Weijie, et al.
Publicado: (2017)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

MULTIPLE KOENEN TUMORS: AN UNCOMMON PRESENTATION
por: Devi, Basanti, et al.
Publicado: (2011)

Urethral Polyp: An Uncommon Presentation of Rhinosporidiosis
por: Pandey, PK, et al.
Publicado: (2014)

Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Hu, Shanliang, et al.
Publicado: (2022)

Liensinine Inhibits Cell Growth and Blocks Autophagic Flux in Nonsmall-Cell Lung Cancer
por: Chang, Minghui, et al.
Publicado: (2022)

Syndecan 4-c-ros oncogene 1 fusion as a mechanism of acquired resistance in epidermal growth factor receptor mutant lung adenocarcinoma
por: Zhu, You-Cai, et al.
Publicado: (2019)

Ylang-ylang oil Not an Uncommon Sensitizer in India
por: Srivastava, PK, et al.
Publicado: (2014)

Poroid Hidradenoma: An Uncommon Cutaneous Adnexal Neoplasm
por: Kumar, Piyush, et al.
Publicado: (2017)

Heterogeneity response to afatinib in gastric cancer patient with uncommon epidermal growth factor receptor (EGFR) mutations: a case report
por: Liu, Qin, et al.
Publicado: (2021)

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer
por: Wu, Jenn-Yu, et al.
Publicado: (2016)

Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review
por: Song, Chengyang, et al.
Publicado: (2022)

Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay
por: Kimura, Shinichi, et al.
Publicado: (2018)

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_15nkfu6mf9mptb06n48k6lrrkm